Skip to main contentSkip to navigationSkip to search

Press release

Camurus updates its investor relations website

28 June 2018

Lund, Sweden — 28 June 2018 — Camurus AB (Nasdaq STO, CAMX) has today updated its investor relations website to include a set of risk factors relevant to investors in the Company.

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Rein Piir, Investor Relations
Tel. +46 (0)70 853 72 92

The information was submitted for publication at 05.32 pm CET on 28 June 2018.

TypeError: Cannot read properties of undefined (reading 'url')